Evidence map›Paper›PMID 35187069›Full record

ArticleFrontiers in molecular biosciences2021

Molecular Docking and Dynamics Studies to Explore Effective Inhibitory Peptides Against the Spike Receptor Binding Domain of SARS-CoV-2.

Suvro Biswas, Shafi Mahmud, Mohasana Akter Mita, Shamima Afrose, Md Robiul Hasan, Mst Sharmin Sultana Shimu, Md Abu Saleh, Gomaa Mostafa-Hedeab, Mohammed Alqarni, Ahmad J Obaidullah and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Metabolites · 2024
    Article
  9. Article
  10. Article
  11. Computational Modeling of the Interactions between DPP IV and Hemorphins.International journal of molecular sciences · 2024
    Article
  12. AnHeliyon · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Suvro BiswasDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Shafi MahmudDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Mohasana Akter MitaDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Shamima AfroseDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Md Robiul HasanDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Mst Sharmin Sultana ShimuDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Md Abu SalehDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Gomaa Mostafa-HedeabPharmacology Department and Health Research Unit-medical College, Jouf University, Jouf, Saudi Arabia.
Mohammed AlqarniDepartment of Pharmaceutical Chemistry, College of Pharmacy, Taif University, Taif, Saudi Arabia.
Ahmad J ObaidullahDrug Exploration and Development Chair (DEDC), Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Gaber El-Saber BatihaDepartment of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.
University of Rajshahi · BDBeni-Suef University · EGDamanhour University · EGKing Saud University · SATaif University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic due to the high transmission and mortality rate of this virus. The world health and economic sectors have been severely affected by this deadly virus, exacerbated by the lack of sufficient efficient vaccines. The design of effective drug candidates and their rapid development is necessary to combat this virus. In this study, we selected 23 antimicrobial peptides from the literature and predicted their structure using PEP-FOLD 3.5. In addition, we docked them to the SARS-CoV-2 spike protein receptor-binding domain (RBD) to study their capability to inhibit the RBD, which plays a significant role in virus binding, fusion and entry into the host cell. We used several docking programs including HDOCK, HPEPDOCK, ClusPro, and HawkDock to calculate the binding energy of the protein-peptide complexes. We identified four peptides with high binding free energy and docking scores. The docking results were further verified by molecular dynamics (MD) simulations to characterize the protein-peptide complexes in terms of their root-mean-square fluctuation (RMSF), root-mean-square deviation (RMSD), radius of gyration (Rg), solvent-accessible surface area (SASA), and hydrogen bond formation. Allergenicity and toxicity predictions suggested that the peptides we identified were non-allergenic and non-toxic. This study suggests that these four antimicrobial peptides could inhibit the RBD of SARS-CoV-2. Future

Indexed as

molecular dynamicspeptide-protein dockingpeptidesRBDSARS-CoV-2

Identifiers

PMID35187069
PMCPMC8851422
OpenAlexW4210728100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.